Table E1. T1, T2, and ADC Data in Dataset A and Dataset B

Diagnosis		I1 (msec)		12 (msec)			ADC (×10 <sup>-3</sup> mm²/sec)		
	No. Sampled*	Mean	SD	No. Sampled*	Mean	SD	No. Sampled*	Mean	SD
NPZ (Dataset A)	120	2247	450	120	169	61	123	1.711	0.269
NPZ (Dataset B)	43	2367	295	43	193	68	43	1.672	0.230
PCa (Dataset A)	73	1628	344	73	73	27	80	0.773	0.311
PCa (Dataset B)	26	1673	208	26	83	28	27	0.704	0.213
Low-grade (Dataset A)	19	1679	422	19	93	30	22	0.999	0.331
Low grade (Dataset B)	4	1655	197	4	120	9	4	1.040	0.050
Int. grade (Dataset A)	40	1682	236	40	66	22	42	0.746	0.238
Int. grade (Dataset B)	15	1725	216	15	75	22	16	0.705	0.170
High grade (Dataset A)	14	1403	419	14	67	28	16	0.529	0.244
High grade (Dataset B)	7	1574	184	7	79	33	7	0.510	0.68
Prostatitis (Dataset A)	27	1707	377	27	79	37	27	0.911	0.239
Prostatitis (Dataset B)	11	1637	318	11	96	38	11	0.850	0.240

Note.—Dataset A is composed of all lesions, dataset B is composed of only those targeted for biopsy. High-grade tumors had a Gleason score of at least 8, intermediate-grade tumors had a Gleason score of 7, low-grade tumors had a Gleason score of 6. Int. = intermediate, PCa = prostate cancer, SD = standard deviation.

Table E2. PI-RADS Scores in Dataset B according to Histology Type

PFRADS Version 2 Score	Prostatitis*	Low - Grade Prostate Cancer <sup>†</sup>	Intermediate- Grade Prostate Cancer <sup>‡</sup>	High-Grade Prostate Cancer
1	3	0	0	0
2	5	2	0	0
3	7	2	2	0
4	0	1	9	1
5	0	0	5	6

Note.—Data are numbers of lesions and/or tumors.

<sup>\*</sup> All counts are for number of regions and/or lesions sampled. NPZ measurements from patients who chose not to undergo biopsy were also included in analysis.

<sup>\*</sup> Includes one lesion with lost data and three lesions that were not well-delineated with MR fingerprinting.

<sup>†</sup> Includes one lesion that was not well-delineated with MR fingerprinting.

<sup>&</sup>lt;sup>‡</sup> Includes one lesion that was not well-delineated with MR fingerprinting.